Target Name: AP4S1
NCBI ID: G11154
Review Report on AP4S1 Target / Biomarker Content of Review Report on AP4S1 Target / Biomarker
AP4S1
Other Name(s): Clathrin-associated/assembly/adaptor protein, sigma 4 | AP4S1 variant 2 | CLAPS4 | AP4S1 variant 1 | CPSQ6 | adaptor related protein complex 4 sigma 1 subunit | Adaptor related protein complex 4 subunit sigma 1, transcript variant 1 | CLA20 | AP-4 adaptor complex subunit sigma-1 | Sigma-1 subunit of AP-4 | OTTHUMP00000178784 | FLJ32366 | Adaptor related protein complex 4 sigma 1 subunit | adaptor related protein complex 4 subunit sigma 1 | AP4S1_HUMAN | Adaptor related protein complex 4 subunit sigma 1, transcript variant 5 | Sigma-4-adaptin | AP-4 complex subunit sigma-1 (isoform 1) | clathrin-associated/assembly/adaptor protein, sigma 4 | Adapter-related protein complex 4 subunit sigma-1 | sigma-4-adaptin | Adaptor related protein complex 4 subunit sigma 1, transcript variant 2 | AP-4 complex subunit sigma-1 | AP4S1 variant 5 | AP-4 complex subunit sigma-1 (isoform 2) | SPG52 | AP47B | Adaptor-related protein complex 4 subunit sigma-1 | Sigma4-adaptin | AP-4 adapter complex subunit sigma-1

Unlocking the Potential of AP4S1: A protein Target for Drug Development

Apoptosis, or programmed cell death, is a natural response to environmental stressors and pathogens, which is crucial for maintaining tissue homeostasis and preventing disease. During apoptosis, cells undergo a series of cellular events that ultimately result in the clearance of damaged or dysfunctional cells. Clathrin-associated/assembly/adaptor protein (AP4S1) is a key regulator of apoptosis, which plays a vital role in maintaining cellular homeostasis and contributes to various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The Protein: Structural and Functional Characterization

AP4S1 is a 21-kDa protein that belongs to the AP family of proteins, which are known to play a crucial role in the regulation of apoptosis. The AP family of proteins consists of several isoforms, including AP-1, AP-2, AP-3, and AP-4S1. These proteins are involved in various cellular processes, including cell adhesion, migration, and apoptosis.

AP4S1 is characterized by a unique structure that includes a nucleotide-binding oligomerization domain (NBO), a transmembrane region, and a cytoplasmic tail. The NBO is a nucleotide-binding domain that plays a critical role in the regulation of apoptosis by allowing the binding of pro-apoptotic regulators, such as Bax and Bad.

The transmembrane region of AP4S1 is characterized by a hydrophobic domain and a variable region that includes a putative cytoplasmic domain and a region responsible for interacting with the cytoskeleton. The cytoplasmic tail of AP4S1 is composed of a unique heptadecapeptide sequence that is involved in the regulation of apoptosis by allowing the binding of pro-apoptotic regulators.

Functional Characterization of AP4S1

Several studies have demonstrated the critical role of AP4S1 in the regulation of apoptosis. For example, studies have shown that AP4S1 plays a role in the regulation of cell apoptosis in various cell types, including cancer cells, neurodegenerative cells, and cardiac cells.

In addition to its role in apoptosis, AP4S1 has also been shown to play a critical role in the regulation of cell adhesion and migration. For example, studies have shown that AP4S1 plays a role in the regulation of cell-cell adhesion and that it is involved in the migration of various cell types, including cancer cells.

Drug Targeting and Therapeutic Applications

The potential of AP4S1 as a drug target makes it an attractive target for drug development in various diseases. Given its role in the regulation of apoptosis and its involvement in cell adhesion and migration, researchers have identified several potential drug targets for AP4S1, including inhibitors of Bax, Bad, and other pro-apoptotic regulators.

One potential drug target for AP4S1 is inhibitors of Bax, which is a key regulator of apoptosis. Bax is involved in the regulation of various cellular processes, including cell adhesion, migration, and apoptosis. Researchers have identified several potential inhibitors of Bax that have been shown to be effective in animal models of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Another potential drug target for AP4S1 is inhibitors of Bad, which is a key regulator of apoptosis and has been shown to play a role in the regulation of various cellular processes, including cell adhesion, migration, and apoptosis. Researchers have identified several potential inhibitors of Bad that have been shown to be effective in animal models of

Protein Name: Adaptor Related Protein Complex 4 Subunit Sigma 1

Functions: Component of the adaptor protein complex 4 (AP-4). Adaptor protein complexes are vesicle coat components involved both in vesicle formation and cargo selection. They control the vesicular transport of proteins in different trafficking pathways (PubMed:10066790, PubMed:10436028). AP-4 forms a non clathrin-associated coat on vesicles departing the trans-Golgi network (TGN) and may be involved in the targeting of proteins from the trans-Golgi network (TGN) to the endosomal-lysosomal system. It is also involved in protein sorting to the basolateral membrane in epithelial cells and the proper asymmetric localization of somatodendritic proteins in neurons. AP-4 is involved in the recognition and binding of tyrosine-based sorting signals found in the cytoplasmic part of cargos, but may also recognize other types of sorting signal (Probable)

The "AP4S1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AP4S1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

AP5B1 | AP5M1 | AP5S1 | AP5Z1 | APAF1 | APBA1 | APBA2 | APBA3 | APBB1 | APBB1IP | APBB2 | APBB3 | APC | APC2 | APCDD1 | APCDD1L | APCDD1L-DT | APCS | APEH | APELA | APEX1 | APEX2 | APH1A | APH1B | API5 | APIP | APLF | APLN | APLNR | APLP1 | APLP2 | APMAP | APOA1 | APOA1-AS | APOA2 | APOA4 | APOA5 | APOB | APOBEC1 | APOBEC2 | APOBEC3A | APOBEC3A_B | APOBEC3B | APOBEC3B-AS1 | APOBEC3C | APOBEC3D | APOBEC3F | APOBEC3G | APOBEC3H | APOBEC4 | APOBR | APOC1 | APOC1P1 | APOC2 | APOC3 | APOC4 | APOC4-APOC2 | APOD | APOE | APOF | APOH | APOL1 | APOL2 | APOL3 | APOL4 | APOL5 | APOL6 | APOLD1 | Apolipoprotein B mRNA editing complex | APOM | APOO | APOOL | APOOP2 | APOOP5 | APP | APPAT | APPBP2 | APPL1 | APPL2 | APRG1 | APRT | APTR | APTX | AQP1 | AQP10 | AQP11 | AQP12A | AQP12B | AQP2 | AQP3 | AQP4 | AQP4-AS1 | AQP5 | AQP6 | AQP7 | AQP7P1 | AQP7P2 | AQP7P3 | AQP7P5 | AQP8